These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 32893721)

  • 1. Understanding the mechanisms of efficacy of fecal microbiota transplant in treating recurrent
    Martinez-Gili L; McDonald JAK; Liu Z; Kao D; Allegretti JR; Monaghan TM; Barker GF; Miguéns Blanco J; Williams HRT; Holmes E; Thursz MR; Marchesi JR; Mullish BH
    Gut Microbes; 2020 Nov; 12(1):1810531. PubMed ID: 32893721
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Microbial bile salt hydrolases mediate the efficacy of faecal microbiota transplant in the treatment of recurrent
    Mullish BH; McDonald JAK; Pechlivanis A; Allegretti JR; Kao D; Barker GF; Kapila D; Petrof EO; Joyce SA; Gahan CGM; Glegola-Madejska I; Williams HRT; Holmes E; Clarke TB; Thursz MR; Marchesi JR
    Gut; 2019 Oct; 68(10):1791-1800. PubMed ID: 30816855
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gut microbiome and plasma lipidome analysis reveals a specific impact of
    Arcay R; Barceló-Nicolau M; Suárez L; Martín L; Reigada R; Höring M; Liebisch G; Garrido C; Cabot G; Vílchez H; Cortés-Lara S; González de Herrero E; López-Causapé C; Oliver A; Barceló-Coblijn G; Mena A
    mBio; 2024 Oct; 15(10):e0134724. PubMed ID: 39189787
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effective fecal microbiota transplantation for recurrent Clostridioides difficile infection in humans is associated with increased signalling in the bile acid-farnesoid X receptor-fibroblast growth factor pathway.
    Monaghan T; Mullish BH; Patterson J; Wong GK; Marchesi JR; Xu H; Jilani T; Kao D
    Gut Microbes; 2019; 10(2):142-148. PubMed ID: 30183484
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fecal microbiota transplantation for the treatment of recurrent Clostridioides difficile (Clostridium difficile).
    Minkoff NZ; Aslam S; Medina M; Tanner-Smith EE; Zackular JP; Acra S; Nicholson MR; Imdad A
    Cochrane Database Syst Rev; 2023 Apr; 4(4):CD013871. PubMed ID: 37096495
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Restoration of short chain fatty acid and bile acid metabolism following fecal microbiota transplantation in patients with recurrent Clostridium difficile infection.
    Seekatz AM; Theriot CM; Rao K; Chang YM; Freeman AE; Kao JY; Young VB
    Anaerobe; 2018 Oct; 53():64-73. PubMed ID: 29654837
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bile acids impact the microbiota, host, and
    McMillan AS; Theriot CM
    Gut Microbes; 2024; 16(1):2393766. PubMed ID: 39224076
    [No Abstract]   [Full Text] [Related]  

  • 8. Changes in microbiota composition, bile and fatty acid metabolism, in successful faecal microbiota transplantation for Clostridioides difficile infection.
    Brown JR; Flemer B; Joyce SA; Zulquernain A; Sheehan D; Shanahan F; O'Toole PW
    BMC Gastroenterol; 2018 Aug; 18(1):131. PubMed ID: 30153805
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunological mechanisms of fecal microbiota transplantation in recurrent
    Soveral LF; Korczaguin GG; Schmidt PS; Nunes IS; Fernandes C; Zárate-Bladés CR
    World J Gastroenterol; 2022 Sep; 28(33):4762-4772. PubMed ID: 36156924
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Changes in microbial ecology after fecal microbiota transplantation for recurrent C. difficile infection affected by underlying inflammatory bowel disease.
    Khanna S; Vazquez-Baeza Y; González A; Weiss S; Schmidt B; Muñiz-Pedrogo DA; Rainey JF; Kammer P; Nelson H; Sadowsky M; Khoruts A; Farrugia SL; Knight R; Pardi DS; Kashyap PC
    Microbiome; 2017 May; 5(1):55. PubMed ID: 28506317
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Longitudinal Bile Acid Composition Changes Following Faecal Microbiota Transplantation for Clostridioides difficile Infection in Children With and Without Underlying Inflammatory Bowel Disease.
    Chen LA; Oliva-Hemker M; Radin A; Weidner M; O'Laughlin BD; Sears CL; Javitt NB; Hourigan SK
    J Crohns Colitis; 2023 Aug; 17(8):1364-1368. PubMed ID: 36988432
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Colonization potential to reconstitute a microbe community in patients detected early after fecal microbe transplant for recurrent C. difficile.
    Kumar R; Maynard CL; Eipers P; Goldsmith KT; Ptacek T; Grubbs JA; Dixon P; Howard D; Crossman DK; Crowley MR; Benjamin WH; Lefkowitz EJ; Weaver CT; Rodriguez JM; Morrow CD
    BMC Microbiol; 2016 Jan; 16():5. PubMed ID: 26758906
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fecal microbiota transplantation for treatment of patients with recurrent
    Voth E; Khanna S
    Expert Rev Anti Infect Ther; 2020 Jul; 18(7):669-676. PubMed ID: 32266848
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gram-Negative Taxa and Antimicrobial Susceptibility after Fecal Microbiota Transplantation for Recurrent Clostridioides difficile Infection.
    Steed DB; Wang T; Raheja D; Waldman AD; Babiker A; Dhere T; Kraft CS; Woodworth MH
    mSphere; 2020 Oct; 5(5):. PubMed ID: 33055258
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fecal Microbiota Transplantation Increases Colonic IL-25 and Dampens Tissue Inflammation in Patients with Recurrent Clostridioides difficile.
    Jan N; Hays RA; Oakland DN; Kumar P; Ramakrishnan G; Behm BW; Petri WA; Marie C
    mSphere; 2021 Oct; 6(5):e0066921. PubMed ID: 34704776
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibiting Growth of Clostridioides difficile by Restoring Valerate, Produced by the Intestinal Microbiota.
    McDonald JAK; Mullish BH; Pechlivanis A; Liu Z; Brignardello J; Kao D; Holmes E; Li JV; Clarke TB; Thursz MR; Marchesi JR
    Gastroenterology; 2018 Nov; 155(5):1495-1507.e15. PubMed ID: 30025704
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fecal microbiota transplantation beyond Clostridioides difficile infections.
    Wortelboer K; Nieuwdorp M; Herrema H
    EBioMedicine; 2019 Jun; 44():716-729. PubMed ID: 31201141
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alteration of gut microbial composition associated with the therapeutic efficacy of fecal microbiota transplantation in Clostridium difficile infection.
    Lee PC; Chang TE; Wang YP; Lee KC; Lin YT; Chiou JJ; Huang CW; Yang UC; Li FY; Huang HC; Wu CY; Huang YH; Hou MC
    J Formos Med Assoc; 2022 Sep; 121(9):1636-1646. PubMed ID: 34836663
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The evaluation of fecal microbiota transplantation vs vancomycin in a Clostridioides difficile infection model.
    Xu Q; Zhang S; Quan J; Wu Z; Gu S; Chen Y; Zheng B; Lv L; Li L
    Appl Microbiol Biotechnol; 2022 Oct; 106(19-20):6689-6700. PubMed ID: 36085529
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recovery of the gut microbiome following fecal microbiota transplantation.
    Seekatz AM; Aas J; Gessert CE; Rubin TA; Saman DM; Bakken JS; Young VB
    mBio; 2014 Jun; 5(3):e00893-14. PubMed ID: 24939885
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.